FDA Approval News 26 September 2025

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

(SEO): Johnson & Johnson (NYSE: JNJ) climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3 Johnson & Johnson stock (NYSE: JNJ) capped a volatile but decisively positive week by closing

13 December 2025

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Updated: December 13, 2025 Milestone Pharmaceuticals Inc. (Nasdaq: MIST) just crossed the line that separates “clinical-stage story stock” from “commercial execution stock.” Late Friday, the company announced FDA approval of CARDAMYST™ (etripamil)—a self-administered nasal spray for adults to convert acute

13 December 2025

FDA Approval · Financial News · Investing · Pharmaceuticals · Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a

9 December 2025

Biotech News · FDA Approval · Investing · NASDAQ:ARWR · Pharmaceuticals · Stock Market

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Updated December 3, 2025 Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just turned into one of the wildest biotech stories of 2025. After the company reported positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular

3 December 2025

Biotechnology · FDA Approval · Financial Forecasts · Investment Analysis · NASDAQ:CAPR · Stock Market

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25

25 November 2025

Company Upgrades · FDA Approval · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases gurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than

30 October 2025

Biotech · FDA Approval · Investment · Pharma News · Stock Market

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a

18 October 2025

Biotech · FDA Approval · Investments · NASDAQ:ATAI · Psychedelics · Stock Market

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Stock Price Surge & Recent Performance Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare

17 October 2025

Biotechnology · FDA Approval · Health News · Medical Breakthroughs · NASDAQ:ACHV · Nicotine Addiction

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Stock Performance & Financial Metrics (as of Oct 7, 2025) Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and

7 October 2025

Biotechnology · FDA Approval · Investment Analysis · Pharma News · Stock Market

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Stock Price Performance (YTD & Recent) Crinetics stock has been volatile but trending upward in 2025, with the recent FDA catalyst propelling it sharply higher. On September 26, 2025, CRNX closed around $45–$46, up roughly +28% in a single day

26 September 2025

Biotech · FDA Approval · Investors · NASDAQ:CRNX · Pharmaceuticals · Stock Market · Stocks

FDA Approval News 26 September 2025 - 13 December 2025